Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine

Human Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 145-152

  Zou, Yan Feng ^a   Wang, Yu ^a   Liu, Ping ^a   Feng, Xiao Liang ^a   Wang, Bin Yan ^a   Zang, Tong Hua ^a   Yu, Xin ^b   Wei, Jing ^c   Liu, Zhong Chun ^d   Liu, Ying ^e   Tao, Ming ^f   Li, Hui Chun ^g   Li, Ke Qing ^h   Hu, Jian ⁱ   Li, Ming ^j   Zhang, Ke Rang ^k   Ye, Dong Qing ^a   Xu, Xi Ping ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f Seventh Hospital of Hangzhou   (China)

^g ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h Sixth People's Hospital of Hebei Province   (China)

ⁱ HARBIN MEDICAL UNIVERSITY   (China)

^j Suzhou Guangji Hospital   (China)

^k SHANXI MEDICAL UNIVERSITY   (China)

more..

Author keywords

Brain derived neurotrophic factor; Health related quality of life; Major depressive disorder; Polymorphism; SSRIs

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE;

ARTICLE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHINA; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FLUOXETINE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MENTAL PROCESSES; MIDDLE AGED; POLYMORPHISM, GENETIC; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; YOUNG ADULT;

EID: 77749301833     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1099     Document Type: Article

References (47)

1. Aydemir C, Yalcin ES, Aksaray S, et al. 2006. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 30: 1256-1260.
2. Cargill M, Altshuler D, Ireland J, et al. 1999. Characterization of singlenucleotide polymorphisms in coding regions of human genes. Nat Genet 22: 231-238.
3. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. 2006. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118: 176-182.
4. Dagher A, Owen AM, Boecker H, Brooks DJ. 1999. Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain 122: 1973-1987.
5. Demyttenaere K, de Fruyt J, Huygens R. 2002. Measuring quality of life in depression. Curr Opin Psychiatry 15: 89-92.
6. Domschke K, Lawford B, Laje G, et al. 2009. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 23: 1-9.
7. Driscoll HC, Basinski J, Mulsant BH, et al. 2005. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 20: 661-667.
8. Egan MF, Kojima M, Callicott JH, et al. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 144-145.
9. Foltynie T, Lewis SG, Goldberg TE, et al. 2005. The BDNF Val66Met polymorphism has a gender specific infiuence on planning ability in Parkinson's disease. J Neurol 252: 833-838.
10. Frodl T, Schüle C, Schmitt G, et al. 2007. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 64: 410-416.
11. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. 2005. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255: 381-386.
12. Gratacòs M, Soria V, Urretavizcaya M, et al. 2008. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J 8: 101-112.
13. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296.
14. Hariri AR, Goldberg TE, Mattay VS, et al. 2003. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23: 6690-6694.
15. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. 1995. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 52: 11-19.
16. Huuhka K, Anttila S, Huuhka M, et al. 2007. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270Tare not associated with response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 257: 31-35.
17. Kang R, Chang H, Wong M, et al. 2009. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol.
18. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. 2002. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 143-148.
19. Kuipers SD, Bramham CR. 2006. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: New insights and implications for therapy. Curr Opin Drug Discov Dev 9: 580-586.
20. Licinio J, Dong C,Wong ML. 2009. Novel sequence variations in the brainderived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66: 488-497.
21. Liu C, Li N, Ren X, Li J, Zhang J, Sun D. 2001. Feasibility of using short Form 36 in Chinese population. J West China Univ Med Sci 32: 39-42.
22. Lotrich FE, Pollock BG. 2005. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45: 1106-1122.
23. Manocchia M, Bayliss MS, Connor J, Keller SD, Shiely J-C, Tasai C. 1997. SF-36 Health Survey Annotated Bibliography, 2nd edn (1988-1996). Health Assessment Lab, New England Medical Center: Boston, MA.
24. Mossner R, Daniel S, Albert D, et al. 2000. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 36: 197-202.
25. Mowla SJ, Farhadi HF, Pareek S, et al. 2001. Biosynthesis and posttranslational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 276: 12660-12666.
26. Nibuya M, Morinobu S, Duman RS. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
27. Pezawas L, Verchinski BA, Mattay VS, et al. 2004. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24: 10099-10102.
28. Phillips ML, Drevets WC, Rauch SL, Lane R. 2003. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry 54: 504-514.
29. Rajewska-Rager A, Skibińska M, Szczepankiewicz A, et al. 2008. Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression. Psychiatr Pol 42: 915-923.
30. Serretti A, Artioli P, Quartesan R. 2005. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15: 61-67.
31. Sheline YI, Gado MH, Kraemer HC. 2003. Untreated depression and hippocampal volume loss. Am J Psychiatry 160: 1516-1518.
32. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. 1996. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93: 3908-3913.
33. Shimizu E, Hashimoto K, Iyo M. 2004. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet 126: 122-123.
34. Siuciak JA, Lewis DR,Wieggnd SJ, Lindsay RM. 1997. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56: 131-137.
35. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. 2003. Association Study of a Brain-Derived Neurotrophic-Factor Genetic Polymorphism and Major Depressive Disorders, Symptomatology, and Antidepressant Response. Am J Med Genet B Neuropsychiatr Genet 123B: 19-22.
36. Ustun TB. The worldwide burden of depression in the 21st century. American Psychiatric Press: Washington, DC; 2001.
37. Verhagen M, van der Meij A, van Deurzen PA, et al. 2010. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15: 260-271.
38. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. 1995. A comparison of methods for the scoring and statistical analysis of the SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33: AS264-AS279.
39. Ware JE Jr, Sherbourne CD. 1992. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30: 473-483.
40. Ware JE, Snow KK, Kosonski M, Gandek B. 1993. SF-36 Health survey manual and interpretation guide. The Health Institute, New England Medical Center: Boston.
41. Wells KB, Sherbourne CD. 1999. Functioning and utility for current health of patients with depression or chronic medical conditions in managed primary care practices. Arch Gen Psychiatry 56: 897-904.
42. Wells KB, Stewart A, Hays RD, et al. 1989. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262: 914-919.
43. Whoqol Group. 1993. Study protocol for the World Health Organisation project to develop a quality if life assessment instrument (Whoqol). Qual Life Res 2: 153-159.
44. Whyte EM, Dew MA, Gildengers A, et al. 2004. Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging 21: 531-554.
45. Wilkie MJ, Smith D, Reid IC, et al. 2007. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 17: 207-215.
46. Yoshida K, Higuchi H, Kamata M, et al. 2007. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 21: 650-656.
47. Zou YF, Wang Y, Liu P, et al. 2010. Association of a brain-derived neurotrophic-factor genetic polymorphism (Val66Met) and severity of depression, efficacy of fluoxetine and its side effects in chinese major depressive patients. Neuropsychobiology 61: 71-78.